CN112079850B - Novel copper binuclear structure metal complex, preparation method and application thereof - Google Patents
Novel copper binuclear structure metal complex, preparation method and application thereof Download PDFInfo
- Publication number
- CN112079850B CN112079850B CN202011011761.9A CN202011011761A CN112079850B CN 112079850 B CN112079850 B CN 112079850B CN 202011011761 A CN202011011761 A CN 202011011761A CN 112079850 B CN112079850 B CN 112079850B
- Authority
- CN
- China
- Prior art keywords
- metal complex
- novel copper
- copper
- novel
- binuclear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000010949 copper Substances 0.000 title claims abstract description 63
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229910052802 copper Inorganic materials 0.000 title claims abstract description 61
- 150000004696 coordination complex Chemical class 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000243 solution Substances 0.000 claims abstract description 27
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 claims abstract description 25
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 239000007864 aqueous solution Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 13
- SXTLQDJHRPXDSB-UHFFFAOYSA-N copper;dinitrate;trihydrate Chemical compound O.O.O.[Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O SXTLQDJHRPXDSB-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000013078 crystal Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000004090 dissolution Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000007789 sealing Methods 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 230000001376 precipitating effect Effects 0.000 claims abstract description 5
- 238000005303 weighing Methods 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 238000000844 transformation Methods 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 34
- 102000008100 Human Serum Albumin Human genes 0.000 description 19
- 108091006905 Human Serum Albumin Proteins 0.000 description 19
- 238000000862 absorption spectrum Methods 0.000 description 9
- 238000002189 fluorescence spectrum Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 244000309466 calf Species 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229910001431 copper ion Inorganic materials 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 150000004699 copper complex Chemical class 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
The invention provides a novel copper binuclear structure metal complex, a preparation method and application thereof, and belongs to the technical field of drug synthesis. The coordination structure of the metal complex is shown in figure 1. The preparation method of the novel copper binuclear structure metal complex comprises the following steps: weighing o-methylbenzoic acid and dissolving in DMF, and adding a small amount of water after complete dissolution to prepare o-methylbenzoic acid solution; adding copper nitrate trihydrate into water to prepare copper nitrate aqueous solution, slowly dripping the copper nitrate aqueous solution into o-methylbenzoic acid solution under stirring, continuing stirring for a period of time after the dripping is finished, placing a sealing film in a shade place, precipitating fine pale blue crystals after 7-10d, filtering and drying to obtain the novel copper binuclear structure metal complex. The metal complex provided by the invention has better anticancer activity and simple preparation method.
Description
Technical Field
The invention relates to the technical field of medicine synthesis, in particular to a novel copper binuclear structure metal complex, a preparation method and application thereof.
Background
Cancer is usually treated by radiation, surgery, chemotherapy and targeted therapy or a combination of these methods, and surgery and radiation therapy can only ensure that no residual cancer cells are present in the operative field. Chemotherapy is a treatment method for killing cancer cells by using chemical substances, and medicines used in the chemotherapy generally identify cancer cells through high-speed cell division, so that high-speed growth cells (bone marrow cells, hair follicle cells and the like) can be affected by the chemotherapeutics, and chemotherapy complications occur. Targeted therapy is a therapeutic approach with target recognition capability, where cancer cell surfaces often contain specific proteins that are not found in normal cells, and targeted drugs can use these proteins to recognize cancer cells and then kill them, while those normal cells without specific proteins cannot, and therefore have much fewer side effects than chemotherapy.
The combination of the transition metal complex and DNA is key to research on novel high-potency and low-toxicity antitumor drugs. Copper is an important element with two valence states, a large number of biological enzymes need copper elements to excite activity, copper elements also participate in the synthesis of various enzymes of a human body, copper ions exist in biological tissues in the form of trace elements of the human body, and research proves that cis-platinum plays a role in resisting tumors but does not participate in copper ion transport proteins, and the reason is that the copper ions have valence variability, and when Cu (II) and Cu (I) are converted, ROS are generated, cancer cells are destroyed, and apoptosis occurs. However, platinum anticancer drugs have large toxic and side effects, and patients with cancer treated usually have serious toxic and side effects such as thrombocytopenia, nausea and vomiting, kidney and nerve injury and the like.
The carboxylic acid metal copper complex has good chemical and biological activity. The relationship between the structure of the metallic copper complex and the action modes and biological activities of DNA and Human Serum Albumin (HSA) is discussed, so that people can be helped to know the action mechanism and pharmacokinetics of drug molecules on the molecular level, and the metallic copper complex has important significance for the synthesis and design of new drugs.
Disclosure of Invention
The invention aims at: aiming at the problems, the invention provides a novel copper binuclear structure metal complex, a preparation method and application thereof.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a novel copper binuclear structure metal complex has the following coordination structure:
wherein, the unit structure diagram of the complex is as follows:
the invention also provides a preparation method of the novel copper binuclear structure metal complex, which comprises the following steps: weighing o-methylbenzoic acid and dissolving in DMF, and adding a small amount of water after complete dissolution to prepare o-methylbenzoic acid solution; adding copper nitrate trihydrate into water to prepare copper nitrate aqueous solution, slowly dripping the copper nitrate aqueous solution into o-methylbenzoic acid solution under stirring, continuing stirring for a period of time after the dripping is finished, placing a sealing film in a shade place, precipitating fine pale blue crystals after 7-10d, filtering and drying to obtain the novel copper binuclear structure metal complex.
In the present invention, preferably, the molar ratio of the o-methylbenzoic acid to the copper nitrate trihydrate is 1:0.8-1.2, and the DMF is excessive.
In the present invention, it is preferable that the dripping time of the copper nitrate aqueous solution is 20 to 40 minutes.
In the present invention, it is preferable that the stirring is continued for a period of time of 20 to 40 minutes.
In the present invention, it is preferable that the drying means drying at 45-55℃for 2-4 hours.
The invention also provides application of the novel copper binuclear structure metal complex in preparing cancer treatment medicines. More specifically, the application in preparing medicaments for treating cervical cancer, lung cancer and liver cancer.
In summary, due to the adoption of the technical scheme, the beneficial effects of the invention are as follows:
1. the invention provides a novel copper binuclear structure metal complex with anticancer activity, and pharmacological analysis is carried out to prove that the novel copper binuclear structure metal complex has better anticancer activity, and is used for treating IC of cells after 48h of actions with cervical cancer cells Hela, lung cancer cells A549 and liver cancer cells HepG2 50 Values were 156.2. Mu.M, 187.8. Mu.M, 62.93. Mu.M, respectively; the preparation method is simple, has low requirements on equipment, and is suitable for popularization and application in the field of anticancer.
2. The invention confirms that the combination mode of the synthesized novel copper binuclear structure metal complex and CT-DNA is insertion type through ultraviolet absorption spectrum, fluorescence spectrum and viscosity; the combination mode of the synthesized novel copper binuclear structure metal complex and HSA is proved by ultraviolet absorption spectrum and fluorescence spectrum to be inserted, and the novel copper binuclear structure metal complex and the HSA have stronger combination and a combination constant K a ＝1.97×10 4 L·mol -1 The number of combined bits is 1.
Drawings
FIG. 1 is a coordination structure diagram of a novel copper binuclear structure metal complex synthesized by the present invention.
FIG. 2 is a block diagram of a novel copper dinuclear structure metal complex synthesized in accordance with the present invention.
FIG. 3 is a graph showing the ultraviolet absorption spectrum of interaction between novel copper binuclear structured metal complex synthesized by the present invention and calf thymus DNA (CT-DNA).
FIG. 4 is a fluorescence spectrum of interaction between novel copper binuclear structured metal complex synthesized by the present invention and calf thymus DNA (CT-DNA).
FIG. 5 is a graph showing the viscosity change of CT-DNA after the novel copper binuclear structural metal complex synthesized by the present invention reacts with calf thymus DNA (CT-DNA).
FIG. 6 is a graph showing the ultraviolet absorption spectrum of the interaction between the novel copper binuclear structural metal complex synthesized by the present invention and Human Serum Albumin (HSA).
FIG. 7 is a fluorescence spectrum of interaction of novel copper binuclear structured metal complex synthesized according to the present invention with Human Serum Albumin (HSA).
FIG. 8 shows cytotoxicity test results of the novel copper binuclear structural metal complex synthesized by the invention on cervical cancer cells Hela, lung cancer cells A549 and liver cancer cells HepG 2.
Detailed Description
The present invention will be further described with reference to the following examples in order to more clearly illustrate the present invention.
It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the present application. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments in accordance with the present application. It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, steps, operations, devices, components, and/or groups thereof.
In order to obtain more complexes with higher anticancer activity, the invention provides the following novel copper binuclear structure metal complexes through research and verification. In an exemplary embodiment of the present invention, a novel copper binuclear structure metal complex is provided, wherein the coordination structure of the complex is shown in FIG. 1, and the unit structure of the complex is shown in FIG. 2.
In the embodiment, o-methylbenzoic acid and DMF ligand react with copper nitrate trihydrate to generate a binuclear penta-coordination complex taking copper ions as the center, and the structure improves the anticancer activity of the complex.
The novel copper binuclear structural metal complex with anticancer activity belongs to a triclinic system, P-1 space group, and the unit cell parameters are a= 10.370 (5) nm, b= 10.536 (4) nm and c= 11.059 (5) nm; α= 62.737 (6) °, β= 73.355 (7) °, γ= 63.231 (7) °; z=1, dc=1.416 mg/m3, F (000) =422.
The invention also provides a preparation method of the novel copper binuclear structure metal complex, which comprises the following steps: weighing o-methylbenzoic acid and dissolving in DMF, and adding a small amount of water after complete dissolution to prepare o-methylbenzoic acid solution; adding copper nitrate trihydrate into water to prepare copper nitrate aqueous solution, slowly dripping the copper nitrate aqueous solution into o-methylbenzoic acid solution under stirring, continuing stirring for a period of time after the dripping is finished, placing a sealing film in a shade place, precipitating fine pale blue crystals after 7-10d, filtering and drying to obtain the novel copper binuclear structure metal complex.
In order to allow the ligand starting material to react well and obtain the target complex, in some embodiments of the invention, the molar ratio of o-methylbenzoic acid to copper nitrate trihydrate is 1:0.8-1.2, the DMF is in excess.
For better reaction, in some embodiments of the invention, the aqueous copper nitrate solution is added dropwise for a period of 20-40 minutes.
For better reaction, in some embodiments of the invention, the continued stirring is for a period of time ranging from 20 to 40 minutes.
In some embodiments of the invention, the drying refers to drying at 45-55deg.C for 2-4 hours.
In order to enable those skilled in the art to more clearly understand the technical solutions of the present application, the technical solutions of the present application will be described in detail below with reference to specific embodiments.
1. Preparation example
Example 1
1mmol of o-methylbenzoic acid is weighed and dissolved in 4ml of DMF, and 2ml of water is added after complete dissolution to prepare o-methylbenzoic acid solution; adding 0.8mmol copper nitrate trihydrate into 4ml water to prepare copper nitrate aqueous solution, slowly dripping the copper nitrate aqueous solution into o-methylbenzoic acid solution within 20min under stirring, continuing stirring for a period of time after dripping, placing a sealing film at a shade place, precipitating fine pale blue crystals after 7d, filtering and drying to obtain the novel copper binuclear structure metal complex.
Example 2
1mmol of o-methylbenzoic acid is weighed and dissolved in 4ml of DMF, and 2ml of water is added after complete dissolution to prepare o-methylbenzoic acid solution; adding 1mmol of copper nitrate trihydrate into 4ml of water to prepare a copper nitrate aqueous solution, slowly dripping the copper nitrate aqueous solution into an o-methylbenzoic acid solution within 30min under stirring, continuing stirring for a period of time after dripping, placing a sealing film at a shade place, separating out fine pale blue crystals after 9d, filtering and drying to obtain the novel copper binuclear structure metal complex.
Example 3
1mmol of o-methylbenzoic acid is weighed and dissolved in 4ml of DMF, and 2ml of water is added after complete dissolution to prepare o-methylbenzoic acid solution; adding 1.2mmol of copper nitrate trihydrate into 4ml of water to prepare a copper nitrate aqueous solution, slowly dropwise adding the copper nitrate aqueous solution into an o-methylbenzoic acid solution within 40min under stirring, continuing stirring for a period of time after the dropwise adding, placing a sealing film at a shade place, separating out fine pale blue crystals after 10d, filtering and drying to obtain the novel copper binuclear structure metal complex.
2. Confirmation of Complex
The blue block crystal structures prepared in examples 1 to 3 were confirmed by single crystal-XRD diffraction, and the data of the crystallography, the main bond length and angle, the main torsion angle, and the like of the complex are shown in tables 1, 2, and 3, respectively.
Table 1 Crystal data of the complexes
TABLE 2 principal bond lengths and bond angles of the complexes
Symmetric transformations for generating equivalent atoms:
#1-x,-y+1,-z+ 1
TABLE 3 principal torsion angles of novel copper metal complexes synthesized according to the invention
Symmetric transformations for generating equivalent atoms:
#1x-1,y,z #2x+1,y,z #3-x,-y,-z
3. the novel copper binuclear structure metal complex synthesized by the invention has ultraviolet absorption spectrum under the action of CT-DNA
The baseline was scanned with Tris-HCl/NaCl buffer at ph=7.2, and the blank background was subtracted. Measurement of 50. Mu. Mol.L in the 200-400 nm range -1 Ultraviolet absorbance spectrum of the complex. 80uL of 2mmo/L CT-DNA solution was added dropwise to the reference cell and the sample cell, respectively, using a pipette. After 15 times of addition, the mixture was allowed to react for 5min, and the solution was scanned.
FIG. 3 is a graph showing the ultraviolet absorption spectrum of interaction between novel copper binuclear structured metal complex synthesized by the present invention and calf thymus DNA (CT-DNA). It can be seen that the complex has a subtractive color effect at 228nm and the absorption peak position undergoes a violet shift as the concentration of CT-DNA increases, thus it is presumed that the complex has an intercalating effect on CT-DNA. Calculating the binding constant K of the complex and DNA b ＝939.61L·mol -1 。
4. The novel copper binuclear structure metal complex synthesized by the invention has fluorescence spectrum under the action of CT-DNA
Will be 8 mu mol.L -1 Ethidium Bromide (EB) and 10 mu mol.L -1 The CT-DNA solution is uniformly mixed with the same volume and reacted for 12 hours. 3mL of the EB-CT-DNA mixed solution was added to the sample cell at an excitation wavelength of 565nm and a scanning speed of 240 nm.s -1 The emission spectrum in the wavelength range of 540 to 700nm was measured. To the EB-CT-DNA system, 40. Mu.L of 1 mmol.L concentration was added dropwise -1 The complex solution is added dropwise for 14 times, and the emission spectrum is measured after each reaction is carried out for 5 min.
FIG. 4 is a fluorescence spectrum of interaction between novel copper binuclear structured metal complex synthesized by the present invention and calf thymus DNA (CT-DNA). It can be seen that the maximum emission wavelength of EB-CT-DNA was always at 596nm, and that the fluorescence intensity gradually decreased as the concentration of the complex increased. At different r= [ complete ]]/[DNA]At this value, the initial fluorescence intensity was reduced from 96.43% to 68.11%. The complex and CT-DNA function mode is similar to EB and is classical insertion mode. Obtaining a quenching rate constant K q ＝2.996×10 11 L·mol -1 ·s -1 . Fluorescence quenching of the complex to EB-DNA is static quenching. Binding rate constant K a ＝5.38×10 3 L·mol -1 Binding site n=1.
5. Influence of the novel copper binuclear structure metal complex synthesized by the invention on CT-DNA viscosity:
the reaction temperature was controlled at 29.0.+ -. 0.1 ℃ with a constant temperature water tank, CT-DNA solution was added to the Ubbelohde viscometer, the concentration of the Complex solution was gradually increased, the concentration ratio of Complex to CT-DNA [ Complex ]/[ DNA ] =0, 0.05, 0.1, 0.15, 0.20, 0.25, 0.30 was made, and the time(s) for the CT-DNA solution to flow through the effective scale of the capillary was recorded in order, and each set of experiments was repeated 3 times, and the average was taken.
FIG. 5 is a graph showing the viscosity change of CT-DNA after the novel copper binuclear structural metal complex synthesized by the present invention reacts with calf thymus DNA (CT-DNA). It can be seen that as the concentration of the complex increases, the viscosity of the DNA increases, indicating that the complex binds to the DNA in an intercalating manner.
6. The novel copper binuclear structure metal complex synthesized by the invention has ultraviolet absorption spectrum under the action of HSA
3mL of 100. Mu. Mol.L was added to the sample cell -1 The reference cell was charged with the same amount of Tris-HCl/NaCl buffer solution and its UV spectrum at 190-400 nm was measured. To each of the two tanks, 10. Mu.L of the complex solution (1 mmol.L) -1 ) 15 times, after each addition, blowing and mixing uniformly, and after 5min of standing at room temperature, scanning and measuring in the same wavelength range.
FIG. 6 is a graph showing the ultraviolet absorption spectrum of the interaction between the novel copper binuclear structural metal complex synthesized by the present invention and Human Serum Albumin (HSA). It can be seen that as the concentration of the complex increases, the absorption peak at 210nm has a subtractive color effect and the absorption peak position has a slight red shift, indicating that the complex interacts with HSA.
7. Fluorescence spectrum of metal complex with novel copper binuclear structure and HSA effect synthesized by the invention
3mL of HSA solution (25. Mu. Mol.L) was added to the sample cell -1 ) The fluorescence spectrum at a wavelength of 300 to 500nm was measured at an excited state of 280 nm. mu.L of the complex solution (1 mmol.L) was added to the sample cell -1 ) After adding for 14 times, blowing and mixing uniformly, standing for 5min at room temperature, and scanning under the same conditions.
FIG. 7 is a fluorescence spectrum of interaction of novel copper binuclear structured metal complex synthesized according to the present invention with Human Serum Albumin (HSA). It can be seen that HSA decreases in absorption intensity with increasing complex concentration at 312nm, but the peak position and peak pattern are substantially unchanged. At different r= [ complete ]]/[HSA]At this value, the initial fluorescence intensity was reduced from 96.39% to 62.72%. Constant value K of quenching rate q ＝1.26×10 12 L·mol -1 ·s -1 Fluorescence quenching of the complex to HSA is static quenching. Binding constant ka=1.97×10 4 L·mol -1 The number of combined bits n=1.
8. The novel copper binuclear structure metal complex synthesized by the invention has cytotoxicity to tumor cells
And (3) determining cytotoxicity of the complex on cervical cancer cells Hela, lung cancer cells A549 and liver cancer cells HepG2 by using an enzyme-labeled instrument. FIG. 8 is a cytotoxicity chart of the novel copper binuclear structural metal complex synthesized by the invention after acting on lung cancer cells A549, cervical cancer cells Hela and liver cancer cells HepG 2. Calculating to obtain the novel copper binuclear structure metal complex and IC of the cell after 48 hours of action of lung cancer cell A549, cervical cancer cell Hela and liver cancer cell HepG2 50 The values were 156.2. Mu.M, 187.8. Mu.M, 62.93. Mu.M, respectively. The novel copper binuclear structure metal complex synthesized by the invention has better anticancer activity on tumor cells, so that the copper binuclear structure metal complex can be applied to the preparation of cancer treatment medicaments, in particular to the application of cervical cancer, lung cancer and liver cancer treatment medicaments.
The foregoing description is directed to the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the invention, and all equivalent changes or modifications made under the technical spirit of the present invention should be construed to fall within the scope of the present invention.
Claims (8)
1. The novel copper binuclear structural metal complex is characterized in that the crystal structure parameters, main bond lengths, bond angles and main torsion angles of the complex are shown in the following tables 1, 2 and 3:
table 1 Crystal data of the complexes
TABLE 2 principal bond lengths and bond angles of the complexes
Symmetric transformations for generating equivalent atoms:
#1-x,-y+1,-z+1
TABLE 3 principal torsion angles of novel copper metal complexes synthesized according to the invention
Symmetric transformations for generating equivalent atoms:
#1x-1,y,z #2x+1,y,z #3-x,-y,-z。
2. the method for preparing a novel copper binuclear structure metal complex as defined in claim 1, comprising the steps of: weighing o-methylbenzoic acid and dissolving in DMF, and adding a small amount of water after complete dissolution to prepare o-methylbenzoic acid solution; adding copper nitrate trihydrate into water to prepare copper nitrate aqueous solution, slowly dripping the copper nitrate aqueous solution into o-methylbenzoic acid solution under stirring, continuing stirring for a period of time after the dripping is finished, placing a sealing film in a shade place, precipitating fine pale blue crystals after 7-10d, filtering and drying to obtain the novel copper binuclear structure metal complex.
3. The method for preparing the novel copper binuclear structure metal complex according to claim 2, which is characterized in that: the molar ratio of the o-methylbenzoic acid to the copper nitrate trihydrate is 1:0.8-1.2, and the DMF is excessive.
4. The method for preparing the novel copper binuclear structure metal complex according to claim 2, which is characterized in that: the dripping time of the copper nitrate aqueous solution is 20-40min.
5. The method for preparing the novel copper binuclear structure metal complex according to claim 2, which is characterized in that: the stirring is continued for a period of time of 20-40min.
6. The method for preparing the novel copper binuclear structure metal complex according to claim 2, which is characterized in that: the drying refers to drying at 45-55 ℃ for 2-4 hours.
7. The use of a novel copper binuclear structured metal complex according to claim 1 for the preparation of a medicament for the treatment of cancer.
8. The use of a novel copper binuclear structured metal complex according to claim 7 for preparing medicines for treating cervical cancer, lung cancer and liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011011761.9A CN112079850B (en) | 2020-09-21 | 2020-09-21 | Novel copper binuclear structure metal complex, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011011761.9A CN112079850B (en) | 2020-09-21 | 2020-09-21 | Novel copper binuclear structure metal complex, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112079850A CN112079850A (en) | 2020-12-15 |
| CN112079850B true CN112079850B (en) | 2023-04-25 |
Family
ID=73739617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011011761.9A Active CN112079850B (en) | 2020-09-21 | 2020-09-21 | Novel copper binuclear structure metal complex, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112079850B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104072524A (en) * | 2014-06-25 | 2014-10-01 | 南开大学 | Water-soluble dinuclear copper complex, and preparation method and application thereof |
| CN106866711A (en) * | 2017-04-01 | 2017-06-20 | 聊城大学 | A kind of 4 methoxysalicyl aldehyde copper complexes and preparation method and application |
| CN108484645A (en) * | 2018-03-26 | 2018-09-04 | 新疆大学 | A kind of pyrazolone-shrinking salicylyl hydrazine closes preparation and the bioactivity of copper complex |
-
2020
- 2020-09-21 CN CN202011011761.9A patent/CN112079850B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104072524A (en) * | 2014-06-25 | 2014-10-01 | 南开大学 | Water-soluble dinuclear copper complex, and preparation method and application thereof |
| CN106866711A (en) * | 2017-04-01 | 2017-06-20 | 聊城大学 | A kind of 4 methoxysalicyl aldehyde copper complexes and preparation method and application |
| CN108484645A (en) * | 2018-03-26 | 2018-09-04 | 新疆大学 | A kind of pyrazolone-shrinking salicylyl hydrazine closes preparation and the bioactivity of copper complex |
Non-Patent Citations (3)
| Title |
|---|
| Copper(II) Complexes of Salicylic Acid Combining Superoxide Dismutase Mimetic Properties with DNA Binding and Cleaving Capabilities Display Promising Chemotherapeutic Potential with Fast Acting in Vitro Cytotoxicity against Cisplatin Sensitive and Resistan;O"Connor, Mark等;《Journal of Medicinal Chemistry》;20121231;第55卷(第5期);1957-1968 * |
| DNA oxidation profiles of copper phenanthrene chemical nucleases;Molphy, Zara等;《Frontiers in Chemistry (Lausanne, Switzerland)》;20151231;第3卷;1-9 * |
| The breast cancer stem cell potency of copper(II) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles;Eskandari, Arvin等;《Dalton Transactions》;20161231;第45卷(第44期);17867-17873 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112079850A (en) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McLaughlin et al. | DNA-metal binding by antitumor-active metallocene dichlorides from inductively coupled plasma spectroscopy analysis: titanocene dichloride forms DNA-Cp2Ti or DNA-CpTi adducts depending on pH | |
| Castan et al. | Platinum and palladium complexes of 3-methyl orotic acid: A route toward palladium complexes with good antitumor activity | |
| Bao et al. | Multifunctional Hf/Mn-TCPP metal-organic framework nanoparticles for triple-modality imaging-guided PTT/RT synergistic cancer therapy | |
| CN108524935A (en) | A kind of Quercetin drug-loading system based on copper sulfide-metal-organic framework material | |
| Keppler et al. | New tumor‐inhibiting metal complexes. Chemistry and antitumor properties | |
| Yang et al. | Irradiation-free photodynamic therapy in vivo induced by enhanced deep red afterglow within NIR-I bio-window | |
| CN104072524B (en) | Water-soluble copper title complex and preparation method and application thereof | |
| CN111961070B (en) | Novel copper metal complex, preparation method and application thereof | |
| CN103861124B (en) | The preparation method of platinum cluster and the application in the preparation and apoptosis agent of tumor | |
| RU2423134C2 (en) | Nanoparticles of heterocrystalline mineral for application as medication | |
| CN112079850B (en) | Novel copper binuclear structure metal complex, preparation method and application thereof | |
| CN109289052A (en) | Nitric oxide and cis-platinum targeting joint controllable drug delivery Nano medication system and preparation | |
| Zheng et al. | Rational design of multi-targeting ruthenium-and platinum-based anticancer complexes | |
| CN109464672A (en) | A kind of platinum medicine/black phosphorus compound and its preparation method and application | |
| Fandzloch et al. | In search of new anticancer drug–Dimethylsulfoxide ruthenium (III) complex with bulky triazolopyrimidine derivative and preliminary studies towards understanding the mode of action | |
| Jia et al. | Tumor–microenvironment activated programmable synergistic cancer therapy by bioresponsive rare-earth nanocomposite | |
| Gao et al. | Achieving a “all in one” Fe/Tm-MOFs with controllable photothermal and catalytic performance for imaging-guided multi-modal synergetic therapy | |
| CN103768620A (en) | Fe/mesoporous silica nano composite material and preparation method and application thereof | |
| CN106939023A (en) | Manganese ion complex and preparation method and application based on chiral tetrahedron-type metal cluster | |
| CN108690061B (en) | Radiotherapy sensitization antitumor drug and preparation method thereof | |
| CN112812131B (en) | Preparation method and application of novel copper metal complex with two-dimensional structure | |
| CN112125926B (en) | Novel chlorine-containing carboxylic acid metal complex, preparation method and application thereof | |
| CN112159419B (en) | Novel copper complex with anticancer activity, preparation method and application thereof | |
| CN112375090B (en) | Preparation method and application of copper complex with one-dimensional trapezoidal chain structure | |
| CN114949247B (en) | Hybrid nanoparticle capable of stably loading DNA and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |